Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Sarcoma
>>
VEGF
>>
Phase 2
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
2
4
6
8
10
12
14
16
18
20
Recentin
(cediranib) / AstraZeneca
Lenvima
(lenvatinib) / Eisai, Merck (MSD)
Sulanda
(surufatinib) / Hutchmed
Tyvyt
(sintilimab) / Eli Lilly
Inlyta
(axitinib) / Pfizer
semaxanib
(SU5416) / Pfizer
Caprelsa
(vandetanib) / Sanofi
Endostar
(recombinant human endostatin) / Simcere
Zaltrap
(ziv-aflibercept IV) / Sanofi
Fruzaqla
(fruquintinib) / Takeda
dovitinib
(TKI258) / Novartis, Oncoheroes
Avzivi
(bevacizumab-tnjn) / Bio-Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Retevmo
(selpercatinib) / Eli Lilly
Vegzelma
(bevacizumab-adcd) / Celltrion
motesanib
(AMG 706) / Takeda
vatalanib
(PTK787) / Novartis, Bayer
Aplidin
(plitidepsin) / PharmaMar, Roche
Balversa
(erdafitinib) / J&J
Cyramza
(ramucirumab) / Eli Lilly
Fotivda
(tivozanib) / Kyowa Kirin, Jazz, LG Chem
Iclusig
(ponatinib) / Takeda, Otsuka
chiauranib
(CS 2164) / Chipscreen
nintedanib
/ Generic mfg.
ENMD-2076
/ CASI
XL820
/ Exelixis
brivanib alaninate
(BMS-582664) / ZAI Lab
emvododstat
(PTC299) / PTC Therap
sitravatinib
(MGCD516) / BeiGene
thrombospondin-1 mimetic
(ABT-510) / AbbVie
tinengotinib
(TT-00420) / TransThera Biosci
